2.48
+0.33(+15.35%)
Currency In USD
| Previous Close | 2.15 |
| Open | 2.46 |
| Day High | 2.57 |
| Day Low | 2.29 |
| 52-Week High | 2.59 |
| 52-Week Low | 0.53 |
| Volume | 13.72M |
| Average Volume | 9.44M |
| Market Cap | 369.53M |
| PE | -1.2 |
| EPS | -2.07 |
| Moving Average 50 Days | 1.92 |
| Moving Average 200 Days | 1.1 |
| Change | 0.33 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of December 30, 2025 at a share price of $2.48. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 5 years ago, it would be worth $0.64 as of December 30, 2025 at a share price of $2.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
GlobeNewswire Inc.
Dec 02, 2025 1:45 PM GMT
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 1:45 PM GMT
Live webcast fireside chat on Thursday, December 4th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generatio
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
GlobeNewswire Inc.
Oct 28, 2025 12:45 PM GMT
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis and fibros